Otilimab

From WikiMD.org
Jump to navigation Jump to search

Otilimab

Otilimab (pronounced oh-ti-li-mab) is a monoclonal antibody that is currently being studied for its potential use in the treatment of various autoimmune diseases, including rheumatoid arthritis.

Etymology

The name "Otilimab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "otili-" prefix does not have a specific meaning and is used to ensure the name is unique.

Mechanism of Action

Otilimab works by targeting and inhibiting the activity of granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that plays a key role in the inflammatory process of autoimmune diseases.

Clinical Trials

As of 2021, Otilimab is in Phase III clinical trials for the treatment of rheumatoid arthritis. The trials are being conducted by GlaxoSmithKline, the pharmaceutical company that developed the drug.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski